Objective
=========

Guidelines mandate demonstration of 95% concordance to another laboratory or method before reporting patient HER2 results. In this analysis, HER2 results obtained with Onco*type*DX, a validated 21-gene recurrence score assay utilizing RT-PCR, were compared with standard fluorescence *in situ*hybridization (FISH) results. The Onco*type*DX HER2 results were then associated with relative risk of breast cancer death.

Methods
=======

Breast cancer specimens from the Kaiser Onco*type*DX study were evaluated for HER2 by FISH with positive \>2.2, equivocal 1.8 to 2.2, and negative \<1.8. HER2 was also assessed with Onco*type*DX (RT-PCR) with positive ≥ 11.5 units, equivocal \>10.7 to \<11.5 units, and negative ≤ 10.7 units (each unit = twofold change in expression). Concordance analyses were conducted following ASCO/CAP guidelines that mandate 95% concordance. Logistic regression was used to estimate association between Onco*type*DX HER2 results and risk of breast cancer death.

Results
=======

Of 568 patients, 12% (67 patients) were HER2^+^by Onco*type*DX and 11% (60) by FISH. Fifty-five patients were HER2^+^by both methods. Of the 12 patients Onco*type*DX HER2^+^but FISH negative, using FISH 11 patients were HER2^-^and one patient was HER2 equivocal. The positive and negative HER2 concordance by FISH and Onco*type*DX was 97% (95% CI = 96% to 99%). Risk of breast cancer death was significantly greater in patients with HER2 ≥ 11.5 (OR = 1.84, 95% CI = 1.13 to 2.99) compared with patients with HER2 ≤ 10.7. However, in patients with HER2 \>10.7 to \<11.5 compared with HER2 ≤ 10.7, there was no greater risk (OR = 0.75, 95% CI = 0.46 to 1.20). There were 71 (12.5%) polysomy cases.

Conclusion
==========

There is a high degree of concordance between RT-PCR using Onco*type*DX and central laboratory FISH assessment of HER2 status.
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